Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | USP5 | P45974 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940834 | 0.95 | MMP3 (0.44) | MMP3COMTUSP5DRD2MCHR1 | |
| SCHEMBL942368 | 0.89 | MMP3 (0.46) | MMP3COMTUSP5DRD2EGFR | |
| SCHEMBL6808425 | 0.83 | MMP3 (0.35) | MMP3COMTUSP5DRD2EGFR | |
| SCHEMBL6809063 | 0.77 | MMP3 (0.43) | MMP3USP5DRD2 | |
| SCHEMBL942270 | 0.74 | DPP4 (0.49) | COMTUSP5ENPP2CYP11B2 | |
| SCHEMBL12911295 | 0.73 | MMP3 (0.52) | MMP3COMTUSP5DRD2MCHR1 | |
| SCHEMBL12911467 | 0.73 | KMT2A (0.41) | — | |
| SCHEMBL5957737 | 0.71 | ADAM17 (0.35) | — | |
| SCHEMBL942531 | 0.70 | MMP13 (0.43) | COMT | |
| SCHEMBL6839896 | 0.70 | MMP13 (0.43) | COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | MMP3 3/4885COMT 2063/4885USP5 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.